image: Schematic representation of the underlying mechanisms of platinum resistance in ovarian cancer.
Credit: He Li, Jia-Jia Sheng, Sheng-An Zheng, Po-Wu Liu, Nayiyuan Wu, Wen-Jing Zeng, Ying-Hua Li, Jing Wang
A review published in Genes & Diseases by researchers from Central South University, Changsha Medical University, and Dali University provides an integrated overview of the diverse biological mechanisms that underlie platinum-resistant ovarian cancer (PROC) and examines emerging therapeutic strategies with clinical promise.
The authors outline how platinum resistance arises from multilayered alterations within tumor cells and their microenvironment. Key contributors include genomic and epigenetic changes, such as TP53 mutations, CCNE1 amplification, BRCA1/2 restoration, and aberrant methylation patterns. Pharmacological resistance mechanisms—notably reduced platinum uptake, increased efflux, and detoxification by glutathione and metallothioneins—further decrease intracellular drug accumulation.
A major focus of the review is the rewiring of DNA damage repair. By enhancing homologous recombination, nucleotide excision repair, and translesion synthesis, PROC cells effectively counter platinum-induced DNA lesions. Complementing these pathways, metabolic reprogramming—including increased glycolysis, fatty acid oxidation, and glutamine–glutathione metabolism—supports cell survival under chemotherapeutic stress.
Beyond tumor-intrinsic changes, the authors emphasize the role of the tumor microenvironment, where cancer-associated fibroblasts, adipocytes, macrophages, mesothelial cells, and ovarian cancer stem cells cooperate to enforce immune suppression, enhance cancer cell fitness, and drive resistance. Concurrently, disruptions in programmed cell death pathways—such as reduced apoptosis and ferroptosis, along with elevated autophagy—further sustain chemoresistance.
Importantly, the review highlights an expanding therapeutic landscape for PROC. Antibody–drug conjugates (ADCs), including mirvetuximab soravtansine (FRα), trastuzumab deruxtecan (HER2), and CDH6-targeting raludotatug deruxtecan, demonstrate meaningful activity in clinical trials. Additional promising strategies include immune-based therapies, WEE1 inhibition for CCNE1-amplified tumors, PI3K inhibitors, GSH-targeting drugs, platinum (IV) prodrug nanotherapeutics, and RNAi-based approaches.
Recognizing the limitations of current diagnostic and treatment frameworks, the authors advocate for a shift toward integrated multi-omics profiling, functional drug testing platforms such as zebrafish and 3D spheroid models, and biomarker-guided patient stratification to enable personalized management of PROC. They emphasize that redefining platinum resistance—beyond static clinical categories—will be essential for improving clinical decision-making and optimizing therapeutic outcomes.
Overall, this comprehensive synthesis provides an essential framework for researchers and clinicians working to overcome one of the most urgent unmet needs in gynecologic oncology—restoring treatment sensitivity and improving survival for women facing platinum-resistant ovarian cancer.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
- Scopus Cite Score: 8.4
- Impact Factor: 9.4
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Disease may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx ).
# # # # # #
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.com
X (formerly Twitter): @GenesNDiseases (https://x.com/GenesNDiseases )
# # # # # #
Journal
Genes & Diseases